Asthma: Addressing consistency in results from basic science, clinical trials, and observational experience

Journal of Allergy and Clinical Immunology

Volumn 109, Issue 5, 2002, Pages S490-S502

  Spahn, Joseph ^a   Covar, Ronina ^a   Stempel, David A ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Asthma; Bronchodilators; Corticosteroids

Indexed keywords

BRONCHODILATING AGENT; CORTICOSTEROID; SALMETEROL;

ARTICLE; ASTHMA; BRONCHODILATATION; CLINICAL RESEARCH; CORTICOSTEROID THERAPY; COST BENEFIT ANALYSIS; HUMAN; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTI-ASTHMATIC AGENTS; ANTI-INFLAMMATORY AGENTS; ASTHMA; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH; STEROIDS;

EID: 0036246647     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1067/mai.2002.122718     Document Type: Article

References (82)

1. 4 synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast
2. Asthma: From bronchoconstriction to airways inflammation and remodeling
3. Human interleukin-5 (IL-5) regulates the production of eosinophils in human bone marrow cultures: Comparison and interaction with IL-1, IL-3, IL-6, and GMCSF
4. Eosinophils and basophils in allergic airway inflammation
5. Interleukin-5, eosinophils, and disease
6. Mitogen plus interleukin 4 induction of Ce transcripts in B lymphoid cells
7. Immunoglobulin heavy-chain switching may be directed by prior induction of transcripts from constant-region genes
8. Interleukin 13, a T cell-derived cytokine that regulates human monocyte and B-cell function
9. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma
10. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma
11. Total eosinophil counts in the management of bronchial asthma
12. Eosinophilic inflammation in asthma
13. Identification of T lymphocytes, macrophages, and activated eosinophils in the bronchial mucosa in intrinsic asthma: Relationship to symptoms and bronchial responsiveness
14. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates
15. Bronchial biopsies in asthma: An ultrastructural, quantitative study and correlation with hyperreactivity
16. Expression of the potent inflammatory cytokines granulocyte-macrophage-colony-stimulating factor and interleukin-6 and interleukin-8, in bronchial epithelial cells of patients with asthma
17. Asthma
18. Airway morphology: Epithelium/basement membrane
19. Mucosal inflammation in asthma
20. Bronchial responsiveness to distilled water and methacholine and its relationship to inflammation and remodeling of the airways in asthma
21. Airways remodeling is a distinctive feature of asthma and is related to severity of disease
22. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children
23. Effects of reducing or discontinuing inhaled BUD in patients with mild asthma
24. Airway remodeling and repair
25. Early interventions in asthma with inhaled corticosteroids
26. The pathology of asthma: An inflammatory disorder
27. Detection of alveolar macrophage-derived IL-1 beta in asthma: Inhibition with corticosteroids
28. Dexamethasone inhibits human IL-2 but not IL-2R gene expression in vitro at the level of nuclear transcription
29. Regulation of IL-3 expression by glucocorticoids in cloned murine T lymphocytes
30. Glucocorticoids suppress the production of interleukin 4 by human lymphocytes
31. Hydrocortisone inhibition of human interleukin-4
32. Inhibition of interleukin-5 gene expression by dexamethasone
33. Prednisolone treatment in asthma is associated with modulation of bronchoalveolar lavage cell interleukin-4, interleukin-5, and interferon-gamma cytokine gene expression
34. Glucocorticoids downregulate gene expression of GM-CSF, NAP-1, IL-8, IL-6, but not M-CSF in human fibroblasts
35. Anti-inflammatory steroids inhibit granulocyte/macrophage colony stimulating factor production by human lung tissue
36. Glucocorticoids suppress the production of tumor necrosis factor by lipopolysaccharide-stimulated human monocytes
37. A comparative study of the effects of an inhaled corticosteroid, BUD, and a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma
38. Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma
39. Placebo-controlled immunopathologic study of four months of inhaled corticosteroids in asthma
40. Effect of high dose inhaled fluticasone propionate on airway inflammation in asthma
41. Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: A placebo-controlled study
42. Inhaled glucocorticoids decrease nitric oxide in exhaled air of asthmatic patients
43. Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma
44. Interactions between corticosteroids and β-adrenergic agonists in asthma disease induction, progression, and exacerbations
45. The complementary role of glucocorticosteroids and long-acting β-adrenergic agonist
46. Airway responsiveness to leukotrienes C4 and D4 and to methacholine in patients with asthma and normal controls
47. Effect of inhaled leukotriene D4 on airway eosinophilia and airway hyperresponsiveness in asthmatic subjects
48. Effect of the leukotriene receptor antagonist pranlukast on cellular infiltration in the bronchial mucosa of patients with asthma
49. NO in exhaled air of asthmatic children is reduced by the leukotriene receptor antagonist montelukast
50. Exhaled nitric oxide before and after montelukast sodium therapy in school-age children with chronic asthma: A preliminary study
51. Montelukast causes prolonged, potent leukotriene D4-receptor antagonism in the airways of patients with asthma
52. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma. A multicenter, randomized, double-blind trial
53. Montelukast for chronic asthma in 6- to 14-year-old children
54. Inhaled glucocorticoids
55. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: A randomized trial
56. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial
57. Salmeterol facilitation of fluticasone-induced apoptosis in eosinophils of asthmatics pre- and post-antigen challenge
58. Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells
59. Theophylline - An immunomodulatory role in asthma?
60. Immunomodulation by theophylline in asthma. Demonstration by withdrawal of therapy
61. Two first-line therapies in the treatment of mild asthma: Use of peak flow variability as a predictor of efficacy
62. Inhaled disodium cromoglycate (DSCG) as maintenance therapy in children with asthma: A systematic review
63. Long-term effects of budesonide or nedocromil in children with asthma
64. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma
65. FEV1 is associated with the risk of asthma attacks in a pediatric population
66. Accuracy of perception of severity of asthma in general practice
67. Physiologic pulmonary function tests. Asthma outcomes
68. Low-dose inhaled fluticasone propionate versus oral zafirlukast in treatment of persistent asthma
69. Effects of 2 weeks of treatment with fluticasone propionate 100 μg b.d. by comparison with zafirlukast 20 mg b.i.d. on bronchial hyper-responsiveness in patients with mild to moderate asthma
70. Low-dose fluticasone propionate compared with montelukast for first-line treatment of persistent asthma: A randomized clinical trial
71. One-year claims analysis comparing inhaled fluticasone propionate with zafirlukast for the treatment of asthma
72. Therapeutic ratio of inhaled corticosteroids in adult asthma: A dose range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function
73. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast
74. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
75. Montelukast added to inhaled beclomethasone in treatment of asthma
76. Montelukast added to budesonide in children with persistent asthma: A randomized double-blind crossover study
77. Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma
78. Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients on concomitant inhaled corticosteroid therapy
79. Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast
80. Inhaled corticosteroids plus salmeterol or montelukast: Effects on resource utilization and costs
81. Two-year retrospective economic evaluation of three dual controller therapies used in the treatment of asthma